EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.11-09

EyePoint Pharmaceuticals (NASDAQ:EYPT) Third Quarter 2024 Results Key Financial Results Revenue: US$10.5m (down 31% from 3Q 2023). Net loss: US$29.4m (loss widened by 133% from 3Q 2023). US$0.54 loss...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482428751?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-09 21:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482428751","market":"us","top_or_hot":-1,"title":"EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","media":"Simply Wall St.","content":"<div>\n<p>EyePoint Pharmaceuticals (NASDAQ:EYPT) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$10.5m (down 31% from 3Q 2023).\nNet loss: US$29.4m (loss widened by 133% from 3Q 2023).\nUS$0.54 loss...</p>\n\n<a href=\"https://finance.yahoo.com/news/eyepoint-pharmaceuticals-third-quarter-2024-130442891.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 21:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/eyepoint-pharmaceuticals-third-quarter-2024-130442891.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>EyePoint Pharmaceuticals (NASDAQ:EYPT) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$10.5m (down 31% from 3Q 2023).\nNet loss: US$29.4m (loss widened by 133% from 3Q 2023).\nUS$0.54 loss...</p>\n\n<a href=\"https://finance.yahoo.com/news/eyepoint-pharmaceuticals-third-quarter-2024-130442891.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYPT","symbol_name":"EyePoint","start_time":0,"source_url":"https://finance.yahoo.com/news/eyepoint-pharmaceuticals-third-quarter-2024-130442891.html","article_id":"2482428751","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482428751","pubTimestamp":1731157482,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqGM:EYPT Earnings and Revenue Growth November 9th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 1.6%. Earnings per share  missed analyst estimates by 2.8%.Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 3.6% from a week ago.We don't want to rain on the parade too much, but we did also find 4 warning signs for EyePoint Pharmaceuticals (2 are concerning!) that you need to be mindful of.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EYPT":"EyePoint"},"translate_title":"EyePoint Pharmaceuticals 2024年第三季度收益：收入超出预期，每股收益滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"EyePoint Pharmaceuticals (NASDAQ:EYPT) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$10.5m (down 31% from 3Q 2023).\nNet loss: US$29.4m (loss widened by 133% from 3Q 2023).\nUS$0.54 loss per share (further deteriorated from US$0.33 loss in 3Q 2023).\n\n\n\n\n  NasdaqGM:EYPT Earnings and Revenue Growth November 9th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nEyePoint Pharmaceuticals Revenues Beat Expectations, EPS Falls Short\n Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 2.8%. \n Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. \nPerformance of the American Pharmaceuticals industry.\n The company's shares are down 3.6% from a week ago. \nRisk Analysis\n We don't want to rain on the parade too much, but we did also find 4 warning signs for EyePoint Pharmaceuticals (2 are concerning!) that you need to be mindful of. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482428751"}